Zhitong Finance App News, Weilizhibo-B (09887.HK) announced that the company's core product, Velisin® (opatisumimab, PD-L1/4-1BB bispecific antibody), has been granted orphan drug qualification by the Ministry of Health, Labor, and Welfare (MHLW) of Japan to treat extrapulmonary neuroendocrine cancer (EP-NEC). This is the third orphan drug qualification obtained by Verisign® after the US Food and Drug Administration (FDA) and the European Commission (EC), marking the further expansion of Velisign®'s global regulatory approval map to major Asian markets.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Weilizhibo-B (09887.HK) announced that the company's core product, Velisin® (opatisumimab, PD-L1/4-1BB bispecific antibody), has been granted orphan drug qualification by the Ministry of Health, Labor, and Welfare (MHLW) of Japan to treat extrapulmonary neuroendocrine cancer (EP-NEC). This is the third orphan drug qualification obtained by Verisign® after the US Food and Drug Administration (FDA) and the European Commission (EC), marking the further expansion of Velisign®'s global regulatory approval map to major Asian markets.